Diaceutics PLC announced that it has secured a contract with a global pharmaceutical company for the provision of technology enabled services, to be delivered via its DXRX platform. The contract value is in excess of $900,000, with the majority of revenue to be recognized in the current financial year, supporting the Company's growth targets and current year forecasts. Diaceutics will collaborate with the client to support the launch of a diagnostic test alongside a new oncology drug. Both the diagnostic test and drug are new to the market and as such the diagnostic test will require adoption by laboratories globally in order for the drug to be prescribed by physicians. This initial contract will involve creating a Quality Assurance standard across 30 laboratories in ten countries to ensure that results and interpretation are consistent wherever the test is undertaken.